Modified Rankin Scale dichotomization was first applied to an acute stroke trial in the NINDS (National Institute of Neurologic Diseases and Stroke) tissue plasminogen activator trial in 1995, in which the grade was divided into favorable outcome (mRS 0–1) and unfavorable outcome (mRS 2–5) [11], Afterwards, dichotomization has become common also in other neurological and neurosurgical studies, with an ongoing debate about the rightful dichotomy cut point [10]. This evidence concerns the gene PLAT and Stroke.